Raymond James Financial Services Advisors Inc. Has $5.22 Million Stock Holdings in Moderna, Inc. (NASDAQ:MRNA)

Raymond James Financial Services Advisors Inc. lowered its stake in Moderna, Inc. (NASDAQ:MRNAGet Rating) by 3.4% during the third quarter, Holdings Channel reports. The firm owned 44,180 shares of the company’s stock after selling 1,550 shares during the period. Raymond James Financial Services Advisors Inc.’s holdings in Moderna were worth $5,224,000 at the end of the most recent reporting period.

A number of other hedge funds also recently modified their holdings of MRNA. Total Clarity Wealth Management Inc. bought a new stake in Moderna during the second quarter worth about $25,000. Oliver Lagore Vanvalin Investment Group bought a new stake in Moderna during the first quarter worth about $30,000. FinTrust Capital Advisors LLC lifted its position in Moderna by 754.5% during the second quarter. FinTrust Capital Advisors LLC now owns 188 shares of the company’s stock worth $31,000 after purchasing an additional 166 shares during the period. Legacy CG LLC bought a new stake in Moderna during the second quarter worth about $34,000. Finally, Castleview Partners LLC lifted its position in Moderna by 14,182.9% during the second quarter. Castleview Partners LLC now owns 4,999 shares of the company’s stock worth $35,000 after purchasing an additional 4,964 shares during the period. Institutional investors own 63.11% of the company’s stock.

Moderna Stock Performance

NASDAQ MRNA opened at $186.64 on Thursday. The company has a market capitalization of $71.70 billion, a price-to-earnings ratio of 6.75 and a beta of 1.71. Moderna, Inc. has a twelve month low of $115.03 and a twelve month high of $228.50. The stock has a fifty day simple moving average of $181.26 and a 200 day simple moving average of $158.74. The company has a quick ratio of 1.80, a current ratio of 2.10 and a debt-to-equity ratio of 0.05.

Moderna (NASDAQ:MRNAGet Rating) last posted its quarterly earnings data on Thursday, November 3rd. The company reported $2.53 earnings per share for the quarter, missing analysts’ consensus estimates of $3.04 by ($0.51). The company had revenue of $3.36 billion during the quarter, compared to analyst estimates of $3.33 billion. Moderna had a net margin of 55.00% and a return on equity of 70.03%. Sell-side analysts expect that Moderna, Inc. will post 21.44 EPS for the current year.

Insider Activity at Moderna

In related news, CEO Stephane Bancel sold 40,000 shares of the stock in a transaction on Thursday, October 20th. The stock was sold at an average price of $120.83, for a total value of $4,833,200.00. Following the completion of the sale, the chief executive officer now directly owns 5,411,946 shares in the company, valued at $653,925,435.18. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. In other Moderna news, President Stephen Hoge sold 1,085 shares of the stock in a transaction dated Tuesday, November 29th. The stock was sold at an average price of $173.80, for a total transaction of $188,573.00. Following the completion of the sale, the president now directly owns 1,627,416 shares in the company, valued at approximately $282,844,900.80. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, CEO Stephane Bancel sold 40,000 shares of the stock in a transaction dated Thursday, October 20th. The stock was sold at an average price of $120.83, for a total value of $4,833,200.00. Following the sale, the chief executive officer now owns 5,411,946 shares of the company’s stock, valued at $653,925,435.18. The disclosure for this sale can be found here. Insiders sold 445,899 shares of company stock worth $74,472,586 over the last three months. Company insiders own 17.30% of the company’s stock.

Analyst Upgrades and Downgrades

A number of research analysts have recently commented on the stock. Chardan Capital cut shares of Moderna from a “buy” rating to a “neutral” rating and increased their target price for the stock from $186.00 to $191.00 in a report on Wednesday, December 14th. They noted that the move was a valuation call. JPMorgan Chase & Co. dropped their price objective on shares of Moderna from $165.00 to $122.00 and set a “neutral” rating for the company in a research note on Monday, October 24th. Morgan Stanley boosted their target price on shares of Moderna from $170.00 to $209.00 and gave the stock an “equal weight” rating in a research note on Friday, December 16th. Cowen dropped their price target on Moderna from $165.00 to $145.00 in a research note on Thursday, October 20th. Finally, Piper Sandler increased their price target on Moderna from $214.00 to $217.00 and gave the company an “overweight” rating in a research note on Tuesday, December 20th. Seven investment analysts have rated the stock with a hold rating and five have given a buy rating to the company’s stock. Based on data from MarketBeat, the stock currently has an average rating of “Hold” and a consensus price target of $192.14.

About Moderna

(Get Rating)

Moderna, Inc, a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, cardiovascular diseases, and auto-immune diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, flu, respiratory syncytial virus, Endemic HCoV, and hMPV+PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, human immunodeficiency virus, herpes simplex virus, and varicella-zoster virus vaccines; and public health vaccines consists of Zika and Nipah vaccines.

See Also

Want to see what other hedge funds are holding MRNA? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Moderna, Inc. (NASDAQ:MRNAGet Rating).

Institutional Ownership by Quarter for Moderna (NASDAQ:MRNA)

Receive News & Ratings for Moderna Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Moderna and related companies with MarketBeat.com's FREE daily email newsletter.